Pain Drug Development Pipeline Review, 2017

Report Hive Market Research Released a New Research Report of 229 pages on Title " Pain Drug Development Pipeline Review, 2017 "with detailed Analysis, Forecast and Strategies.

Pain Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the pain pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Osteoarthritis Pain, Migraine pain and Neuropathic Pain, therefore covering a number of the most difficult-to-treat chronic and acute pain subtypes.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Finally neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury, in which the nerve fibres could be damaged resulting in the generation of abnormal signals. However, it is exhibited in a range of diseases and has no specific identifiable cause.

The size of these pipelines ranges from 62 products in osteoarthritis pain to 249 in neuropathic pain. Within osteoarthritis pain, prostaglandin G/H synthases 1 and 2 and the nerve growth factor receptors are being studied by the most pipeline products; while the prostaglandin receptors are frequently targeted by already approved marketed products, the nerve growth factor receptors are not.

In migraine, it is the 5-hydroxytryptamine (serotonin) receptors 1D and 1B which are being most frequently studied, again reflecting the composition of the market for this indication. However, the calcitonin gene related peptide and its receptor, also very frequently targeted, are not yet present in the migraine market. Finally, the favoured targets of neuropathic pain are the sodium channel protein type 9 (Nav1.9) and the mu type opioid receptor. While the latter is already heavily targeted in the pain market, the former is not.

Request Free Research Sample: https://www.reporthive.com/request-sample.php?id=931459

Scope

- Which companies are the most active within the pipeline for pain therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of pain therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 5
List of Figures 11
Introduction 12
GBI Research Report Coverage 12
Osteoarthritis Pain - Overview 12
Migraine - Overview 12
Neuropathic Pain - Overview 12
Therapeutics Developmen

Browse Full Report: https://www.reporthive.com/details/pain-drug-development-pipeline-review-2017

Osteoarthritis Pain 13
Migraine 20
Neuropathic Pain 28
Therapeutics Assessment 45
Osteoarthritis Pain 45
Migraine 55
Neuropathic Pain 65
Companies Involved in Therapeutics Development 78
Osteoarthritis Pain 78
Migraine 98

Key questions answered in the report

· What will the market size and the growth rate be in 2021?
· What are the key factors driving the Pain Drug Development Market?
· What are the key market trends impacting the growth of the Pain Drug Development Market?
· What are the challenges to market growth?
· Who are the key vendors in this market space?
· What are the market opportunities and threats faced by the vendors in the Pain Drug Development Market?
· Trending factors influencing the market shares of the Americas, APAC, and EMEA?
· What are the key outcomes of the five forces analysis of the Pain Drug Development Market?

We are a leading repository of market research reports and solutions catering to industries like Comm & Technology, Energy & Power, Food And Beverages, Automotive & Transportation, Healthcare & Life Science etc. This large collection of reports assists organizations in decision-making on aspects such as market entry strategies, market sizing, market share analysis, competitive analysis, product portfolio analysis and opportunity analysis among others. We also assist in determining the best suited and targeted report from our large repository of global reports, company-specific reports and country-level reports.

Mike Ross
Marketing Manager
mike.ross@reporthive.com
http://www.reporthive.com
Phone: +1 312-604-7084
Sainath Nagar, Vadgaon Sheri,
Pune, Maharashtra 411014

This release was published on openPR.